Abstract: Lung adenocarcinomas have diverse genetic and morphological backgrounds and are usually classified according to their distinct oncogenic mutations (or so-called driver mutations) and histological subtypes (the de novo classification proposed by the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society [IASLC/ ATS/ERS]). Although both these classifications are essential for personalized treatment, their integrated clinical effect remains unclear. Therefore, we analyzed 981 lung adenocarcinomas to detect the potential correlation and combined effect of oncogenic mutations and histological subtype on prognosis. Analysis for oncogenic mutations included the direct sequencing of EGFR, KRAS, HER2, BRAF, PIK3CA, ALK, and RET for oncogenic mutations/rearrangements, and a rereview of the IASLC/ATS/ERS classification was undertaken. Eligible tumors included 13 atypical adenomatous hyperplasia/adenocarcinoma in situ, 20 minimally invasive adenocarcinomas, 901 invasive adenocarcinomas, 44 invasive mucinous adenocarcinomas, and three other variants. The invasive mucinous adenocarcinomas had a lower prevalence of EGFR mutations but a higher prevalence of KRAS, ALK, and HER2 mutations than invasive adenocarcinomas. Smoking, a solid predominant pattern, and a mucinous component were independently associated with fewer EGFR mutations. The ALK rearrangements were more frequently observed in tumors with a minor mucinous component, while the KRAS mutations were more prevalent in smokers. In addition, 503 patients with stage I-IIIA tumors were analyzed for overall survival (OS) and relapse-free survival. The stage and histological pattern were independent predictors of relapse-free survival, and the pathological stage was the only independent predictor for the OS. Although patients with the EGFR mutations had better OS than those without the mutations, no oncogenic mutation was an independent predictor of survival. Oncogenic mutations were associated with the novel IASLC/ATS/ERS classification, which facilitates a morphology-based mutational analysis strategy. The combination of these two classifications might not increase the prognostic ability, but it provides essential information for personalized treatment.
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Introduction
Over the past decades, the treatments for lung cancer have progressed with the recognition of interindividual variation, leading to classification according to subtype and histologybased treatment strategies. [1] [2] [3] [4] Lung adenocarcinoma is one of the histological subsets accounting for nearly 40% of all lung cancer cases. Its treatments have further advanced after the delineation of disease subgroups harboring specific mutant oncogenic kinases, submit your manuscript | www.dovepress.com
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hu et al such as epidermal growth factor receptor (EGFR), which respond to their corresponding tyrosine kinase inhibitors (TKIs). [5] [6] [7] With the increasing number of the so-called "driver" mutations identified in lung adenocarcinoma, 8 other prime examples, such as anaphylactic lymphoma kinase (ALK) and its inhibitor crizotinib, continue to emerge and provide patients with molecular-based treatments. [9] [10] [11] [12] Therefore, lung adenocarcinomas could be classified in the genetic dimension by using mutant genes corresponding to the potential targeted molecular therapies. 13 Recently, a new classification system was proposed by the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) to characterize further lung adenocarcinoma in the morphological dimension. 14 This approach segregates primary lesions considering their invasiveness and predominant histological pattern. Previous studies showed the association of this novel classification system with tumor metabolism, 15, 16 response to radiation, 17 and prognosis prediction, [17] [18] [19] [20] [21] indicating its role as a supplement to stage-dependent clinical decisionmaking.
To better characterize patients for clinical evaluation and treatment, we sought to evaluate whether these two classification systems correlate with each other and whether the combination of these two dimensions might produce subgroups that are more homogeneous. Several previous studies, all with relatively small sample sizes, reported a possible relationship between the IASLC/ATS/ERS classification and the EGFR and/or the KRAS mutation status. [21] [22] [23] [24] [25] In this study, we comprehensively analyzed 1,015 lung adenocarcinomas for driver mutations by using the IASLC/ATS/ERS classification and incorporated these data with the clinicopathological characteristics to evaluate their mutual correlation and potential role in prognostic prediction.
Materials and methods
Patients and tissues
From February 2007-July 2012, surgically resected tumor samples from 1,015 patients with newly diagnosed, pathologically confirmed lung adenocarcinomas were consecutively collected by the Department of Thoracic Surgery at the Fudan University Shanghai Cancer Center. These tumor samples were taken at the time of surgical resection, and the tumor content was at least 20% evaluated by the pathologist. Among them, 24 patients received neoadjuvant chemotherapy, and ten cases that could not be pathologically/genetically classified were excluded; therefore, 981 completely resected lung adenocarcinomas were assessed for their genetic and morphological classification ( Figure S1 ).
Genomic deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) was extracted from frozen tissues as per standard protocols (RNeasy Mini Kit and QiAamp DNA Mini Kit; Qiagen NV, Venlo, the Netherlands). The total RNA samples were then reverse-transcribed into single-stranded cDNA by using a RevertAid™ First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA). Clinical and pathological data, including the age at diagnosis, sex, smoking history, and the pathological tumor, node, metastasis stage, were prospectively collected for analyses. Patients were followed-up in the clinic and/or by telephone for disease recurrence and survival from the date of diagnosis. This research was approved by the institutional review board of the Fudan University Cancer Center, Shanghai, People's Republic of China. All participants provided written informed consent.
Morphological and genetic classification evaluation
The novel classification of adenocarcinoma was reviewed by two pathologists (Yuan Li and Lei Shen), according to the criteria of the IASLC/ATS/ERS classification as previously described. 24, 25 For invasive adenocarcinoma, the predominant pattern was recorded and designated into three pattern groups for survival analysis, as suggested by previous studies: 15, 17, 19, 26 group 1 refers to lepidic predominant (LEP); group 2 refers to acinar predominant (ACN) or papillary predominant (PAP); and group 3 refers to micropapillary predominant (MP) or solid predominant (SLD) adenocarcinomas. Invasive mucinous adenocarcinoma (IMA) and other variants of invasive adenocarcinoma were analyzed separately, by using the IASLC/ATS/ERS guidelines.
A comprehensive analysis for driver mutations, including the EGFR, KRAS, HER2, BRAF, ALK, RET, and PIK3CA, was carried out as previously described. 13, 24, 27, 28 Briefly, EGFR (exons [18] [19] [20] [21] [22] , HER2 (exons 18-21), KRAS (exons 2-3), BRAF (exons [11] [12] [13] [14] [15] , and PIK3CA (exons [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] were amplified by using the polymerase chain reaction (PCR) with cDNA used for Sanger sequencing. The ALK and RET rearrangements were screened by using PCR and quantitative real-time PCR with cDNA 27, 28 and confirmed with fluorescence in situ hybridization in formalin-fixed paraffin-embedded specimens. 27, 28 statistical analyses Associations between genetic, morphological, and clinical characteristics were analyzed by using the χ 2 test or 
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Genetic and morphologic classifications in lung adenocarcinoma Figure S1 ). The survival curves were estimated by using the Kaplan-Meier method with differences in survival assessed using the log-rank test. The multivariate survival analysis was conducted using the Cox proportional hazards model. All data were analyzed with SPSS 16.0 (SPSS Inc., Chicago, IL, USA). The two-sided significance level was set at P,0.05.
Results
In total, completely resected tumors from 981 patients with lung adenocarcinoma were eligible for examination and analyses, including 13 Table 1 , and the overall mutational spectrum is shown in Figure S2 .
(Characteristics of the three colloid/enteric adenocarcinomas are shown in Table S3 .)
Driver mutations partially correlate with IASLC/ATS/ERS classification
The spectrum of driver mutations across the IASLC/ATS/ ERS classifications is illustrated in Figure 1 . All driver mutations were mutually exclusive except in 18 patients with coexisting EGFR and PIK3CA mutations, four with both the KRAS and PIK3CA mutations, and one with both the RET and PIK3CA mutations. The overall frequency of the EGFR mutation was 64.7%, much higher than that reported in the Caucasian population, while the overall frequency of the KRAS mutation was 7.1%, much lower than that reported in Caucasian patients. 29 MIA has a comparable mutation spectrum to invasive adenocarcinoma in terms of the frequency of the EGFR mutants (P=0.334) and pan-negative samples (P=1.000). Surprisingly, the samples from preinvasive lesions (atypical adenomatous hyperplasia [AAH]/adenocarcinoma in situ [AIS]) were found to have a significantly lower EGFR mutation frequency (P=0.013), but higher HER2 and BRAF mutation frequencies than invasive adenocarcinoma (P=0.015 and P=0.003, respectively).
submit your manuscript | www.dovepress.com
Dovepress
1426
hu et al Interestingly, IMA was found to have a significantly lower prevalence of EGFR mutations but a higher prevalence of KRAS, HER2, and ALK mutations than invasive adenocarcinoma (P,0.001, P,0.001, P=0.003, and P=0.003, respectively). The difference was significant even when compared with MIA (P,0.001, P=0.001, P=0.656, and P=0.049, respectively) or LEP invasive adenocarcinoma (P,0.001, P,0.001, P=0.030, and P=0.007, respectively).
For 901 invasive adenocarcinomas, the prevalence of EGFR mutants (P=0.404) and pan-negative samples (P=0.995) was relatively equal among the LEP, ACN, PAP, and MP patterns. However, SLD patterns had a significantly lower EGFR mutation frequency (P,0.001) and a higher pan-negative frequency (P,0.001) than non-SLD patterns. Table S1 summarizes the correlation between driver mutations and clinical and pathological characteristics. Univariate analysis revealed a significant association of KRAS mutations with men (P,0.001), smokers (P,0.001), and SLD pattern adenocarcinomas (P,0.001), and the tendency for the ALK fusions was significantly associated with invasive adenocarcinomas with a minor mucinous component (P,0.001). Multivariate analysis (Table S2) confirmed smoking status and SLD pattern as independent factors predicting fewer EGFR mutants and more pan-negative tumors. The pannegative tumors were also independently associated with older age (.60 years), although it was not significant in the univariate analysis, while EGFR mutant tumors were also independently correlated with the absence of a mucinous component. Characteristics of one colloid, two enteric, and four stage III-IV adenocarcinomas with LEP pattern are listed in Table S3 .
Mucinous component and smoking status indicate mutational test priority
Considering the predominant prevalence of EGFR mutations in this Chinese cohort, independent factors, including a minor mucinous component, smoking status, and SLD pattern were used to investigate a practical mutational test strategy in invasive adenocarcinomas. As demonstrated in Figure 2 , the frequency of EGFR mutations decreased and that of pannegative tumors increased in smokers and in patients with SLD adenocarcinoma. The KRAS mutations were more common in smokers without a mucinous component, and the ALK mutations were more common in invasive adenocarcinomas 
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Genetic and morphologic classifications in lung adenocarcinoma with a minor mucinous component. EGFR remains the major genetic subtype in either subgroup.
impact of genetic and morphological classifications on prognosis
The survival data of eight patients with preinvasive lesions or MIAs, 478 patients with stage I-IIIA invasive adenocarcinoma, and 17 patients with stage I-IIIA IMA were collected for RFS and OS analyses. Of these, 277 received adjuvant chemotherapy, with 266 (96.0%) treated with platinum-based doublets and eleven (4.0%) with a single regimen. No patient received TKIs as adjuvant chemotherapy. The median follow-up time was 19.0 months. Table S4 , the sex, smoking status, pathological stage, adjuvant chemotherapy, and histological pattern group were significantly associated with RFS, while the pathological stage, adjuvant chemotherapy, pattern group, and EGFR mutations were significantly associated with OS. As shown in Table 2 , the pathological stage and histological pattern group remained the only independent predictors of RFS, and the pathologic stage was the only independent predictor of OS in the multivariate analysis.
As listed in
None of the eight patients with preinvasive lesions or MIA had disease recurrence or death during follow-up. Predominant histological pattern and pattern group were significantly associated with RFS (P,0.001 and P,0.001, respectively) and OS (P=0.055 and P=0.018, respectively). Multivariate analysis confirmed the pattern group as an independent predictor for RFS (P=0.001) but not for OS (P=0.406). The group 1 (LEP) patients had the most favorable outcome, followed by group 2 (CAN and PAP), and by group 3 (SLD and MP) ( Figure S3 ). Patients with IMA had a moderate-to-poor prognosis that could not be differentiated from group 2 or group 3 ( Figure S3 ). Generally, driver mutations had no impact on RFS (P=0.290) or OS (P=0. Figure S4) .
We further investigated whether genetic classification had an impact on survival when it was combined with morphological classification. In the subgroup analysis for patients with stage IIIA tumors (Figure 3 ), the pattern group 2 (ACN and PAP) tumors harboring KRAS/HER2/BRAF mutations conferred significantly poorer RFS than group 2 and even group 3 (SLD and MP) tumors that did not harbor any KRAS/HER2/ BRAF mutations. However, there was no significant difference between KRAS/HER2/BRAF mutants and the wild-type tumors in group 3 patients. Although the comparison of the OS did not show any statistical significance, a similar trend suggested that the combination of genetic and morphological classification might define a distinct prognostic subgroup.
We also found that in the subcohort of patients harboring a wild-type EGFR gene, the histological pattern group was no longer an independent predictor of RFS, but the adjuvant chemotherapy was ( Table 2 ), suggesting that genetic factors might modify the impact of morphological classification on prognosis.
Discussion
The diverse responses and/or prognoses of patients reinforce that interindividual variation exists, and that specialized treatment is required. Recurrent kinase mutation analysis provides a genetic approach to scale these variations, according to the patients' potential responses to targeted therapy. The novel IASLC/ATS/ERS classification system provides a morphological predictor of prognosis, and possibly, of therapy response. Therefore, the integration of these two classifications might help to combine both kinds of information, potentially extending our understanding of lung adenocarcinoma. Although detected in several small set studies, the correlation between these two classification systems is still far from clear and their common impact on prognosis remains unknown. To the best of our knowledge, this is the largest scale study that used a comprehensive approach to investigate the correlation between the IASLC/ATS/ERS classification and the driver mutations and to evaluate their combined impact on prognosis.
The distribution of driver mutations partially correlated with the novel IASLC/ATS/ERS classification system. The MIA had a higher EGFR mutation frequency than invasive adenocarcinoma and IMA. For invasive adenocarcinoma, LEP had the largest EGFR mutation frequency followed by 
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Genetic and morphologic classifications in lung adenocarcinoma PAP, ACN, MP, and SLD. SLD was an independent predictor of KRAS and RET mutations, and the existence of a minor mucinous component was independently associated with a relatively high prevalence of HER2 and ALK mutations. Either SLD or a mucinous component indicated a reduced chance of harboring a mutant EGFR gene. However, no morphological characteristics could identify a specific genetic subtype, suggesting that genetic heterogeneity remains a morphological scale. One interesting finding in this study cohort was that preinvasive lesions (AAH/AIS) had a relatively lower EGFR mutation frequency but had a higher frequency of HER2 and BRAF mutations. This finding greatly differs from the report by Yoshizawa et al, in which more than 80% of AIS patients harbored an EGFR mutation. 21 In addition, Sakamoto et al reported that AAH had a higher frequency of KRAS mutation (33%), which was low in AIS (12%) and MIA (8%). 30 Therefore, the mechanism behind the carcinogenesis driven by the mutant kinases and the pathological pathway underlying this process still warrant further investigation.
One of the great developments of the novel IASLC/ATS/ ERS classification system is the replacement of previous bronchioloalveolar carcinoma with MIA, LEP, and IMA. 14 Earlier studies showed the association of the bronchioloalveolar carcinoma subtype with EGFR mutations. 31 Given this novel morphological insight, we found that IMA was associated with fewer EGFR mutations and more KRAS, HER2, and ALK mutations, indicating a different genetic background in this group of tumors. Survival analysis also revealed a poorer RFS and OS for patients with IMA than for patients with MIA or LEP. These data support the separation of IMA from the old bronchioloalveolar carcinoma classification.
The National Comprehensive Cancer Network guidelines recommend that biomarkers including EGFR and ALK should be initially tested for advanced nonsquamous non-small-cell lung cancer. 32 While the molecular testing guidelines by the College of American Pathologists, the IASLC, and the Association for Molecular Pathology 33 suggest that the laboratories may implement testing algorithms to enhance the efficiency of molecular testing of lung adenocarcinomas. When incorporated with the novel IASLC/ATS/ERS classification, we may propose an efficient mutation test algorithm for Chinese or East Asian patients (Figure 4) 
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hu et al predominant prevalence. As a mucinous component and smoking were found to harbor diverse mutation spectrums in invasive adenocarcinoma, tumors with a mucinous component are recommended to receive ALK testing with or after testing for EGFR mutations, and patients who are smokers are recommended to be screened for the KRAS mutations with or after screening for EGFR mutations. IMA had a unique mutation distribution; therefore, this group of patients is recommended to undergo KRAS testing first, followed by ALK and EGFR mutation detection. Given that more and more oncogenes, including KRAS 34 and RET, are targetable (ie, cabozantinib), 35 this testing strategy might not only facilitate laboratory work flow but also the physicians' decision-making on target therapy.
The novel IASLC/ATS/ERS classification is excellent for outcome prediction; patients with preinvasive lesions and MIAs had no recurrence or death during follow-up. For invasive adenocarcinoma, a previous study showed that pattern group was an independent predictor for both diseasefree survival and OS; 17 however, in this study cohort, we only validated the pattern group as an independent predictor of RFS, but not for OS. Potential reasons for this discrepancy might be the relatively short period of follow-up in our study, and that only patients with stage I-IIIA tumors were included in the survival analysis in our study to achieve more reproducible results in the surgical setting. Genetic classification according to driver mutations generally had no independent impact on the RFS or OS, although a trend toward improved outcomes for EGFR mutant tumors, similar to what was observed in previous studies of resected non-small-cell lung cancers, 36 was observed. The addition of morphological classification by using the IASLC/ATS/ERS criteria increased the discriminative ability for predicting outcome; however, patients were still grouped in several specific patterns (eg, ACN and PAP). Therefore, the necessity to identify further patients with different outcomes is questioned. Kadota et al assessed the expression level of thyroid transcription factor-1 by using immunohistochemical staining to identify patients with early disease recurrence in stage I lung adenocarcinomas. 18 In this study, we found that the KRAS/HER2/BRAF mutations identified a distinct subgroup of patients with stage IIIA tumors who showed early recurrence even after they received adjuvant chemotherapy; therefore, more aggressive perioperative treatment of these patients might be warranted. We also revealed that the histological pattern group was not an independent predictor of survival for the subcohort of patients harboring a wild-type EGFR gene, suggesting that the genetic classification might also supersede morphological classification for prognosis prediction.
Although strengthened by the consecutively collected, completely resected samples as well as the large sample size, several limitations of the current study still need to be noted. First, we only considered the predominant histological pattern in our analysis. However, this might not interfere with the result, as previous studies have sufficiently proved that only the predominant pattern plays a role in survival prediction, 17 and there might not be intratumoral heterogeneity for mutation analysis in mixed-subtype tumors. 23 Second, the use of EGFR TKIs, radiation therapy data was not included. Therefore, further investigation into whether the patients with an EGFR mutant gene have different responses to EGFR TKIs of radiation therapy considering their morphological subtype would be of great value.
Conclusion
This study demonstrated that the novel IASLC/ATS/ERS classification was associated with oncogenic mutations, which further increases our understanding of interindividual variation among lung adenocarcinomas and helps to stratify the mutational analysis strategy in clinical practice. The combination of these two systems provides essential information for specialized treatment, and their combined impact for targeted therapy still requires further investigation. The histological subtype based algorithm is an efficient implement to the CAP/IASLC/AMP molecular testing guideline for East Asian patients. 
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